Features
A First Look at the LUGANO Data
Charles C. Wykoff, MD, PhD, and Carl Regillo, MD, FACS, examine phase 3 EYP-1901 findings presented for the first time at Retina Society 2026.
By Charles C. Wykoff, MD, PhD, Carl D. Regillo, MD, FACS
New Data on Laru-Zova in XLRP
Phase 2 DAWN results provide additional evidence on safety and visual function as the laru-zova program advances through the pivotal VISTA trial.
By Aleksandra V. Rachitskaya, MD, FASRS
Four-Year Data Show Durable MCO-010 Effect
Long-term follow-up of RESTORE participants shows sustained visual acuity improvements after a single intravitreal administration of the optogenetic therapy.
By Christine Nichols Kay, MD
Study Supports 30-Second Chlorhexidine Protocol for IVI
Aqueous chlorhexidine 0.05% significantly reduced conjunctival bacteria within 30 seconds, supporting a shorter antisepsis protocol using a less irritating alternative to povidone-iodine.
By Jim Gallagher, senior managing editor
Tracking Fluid Resolution After Photodynamic Therapy
A single-patient analysis found that more than half of estimated subretinal fluid volume resolved within 9 days of half-fluence PDT for chronic CSCR.
By Jim Gallagher, senior managing editor
Epiretinal Membrane Removal May Reduce Injection Burden in nAMD
In a small retrospective study, two-thirds of patients stopped or reduced anti-VEGF injections following surgery.
By Jim Gallagher, senior managing editor
Avacincaptad Pegol and Anti-VEGF in Real-World Practice
An IRIS Registry analysis of more than 13,000 eyes found that concomitant anti-VEGF use for nAMD or CNV did not substantially alter complement inhibitor treatment.
By Jim Gallagher, senior managing editor
The Changing Economics of Retina
Twenty years of Medicare data show rising procedure volume, changing treatment patterns, and a 32% decline in inflation-adjusted reimbursement.
By Jim Gallagher, senior managing editor
New Tiespectus Data in Treatment-Naïve nAMD
Diana V. Do, MD, reviews phase 1/2a findings for the bispecific Tie2 agonist and VEGF inhibitor, presented at Retina Society 2026.
By Diana V. Do
Timing of Stage 2 ROP May Help Identify High-Risk Eyes
In a study presented at Retina Society, stage 2 diagnosis at an earlier postmenstrual age was associated with higher treatment rates and a greater proportion of zone I disease.
By Jim Gallagher, senior managing editor
Star-DDS: A New Approach to Aflibercept Durability
Jennifer Kang-Mieler, PhD, discusses a biodegradable drug-delivery platform designed to provide sustained intravitreal aflibercept delivery for 6 months or longer.
By Diana V. Do
New Gildeuretinol Findings From Retina Society
Kenneth C. Fan, MD, MBA, and Baruch D. Kuppermann, MD, PhD, presented TEASE findings on the safety and efficacy of oral gildeuretinol and discussed the phase 3 NORTHSTAR trial.
By Baruch D. Kuppermann, MD, PhD, Kenneth C. Fan, MD, MBA, Diana V. Do, MD
Statin Use Linked to Lower PVR Risk
A retrospective study presented at Retina Society 2026 found lower rates of PVR and complex reoperation after RD repair among patients taking systemic statins.
By Jim Gallagher, senior managing editor
Sura-vec Shows Durable Effect at 3 Years
Nikolas London, MD, MS, FACS, discusses long-term findings with gene therapy ABBV-RGX-314 in patients with nonproliferative diabetic retinopathy.
By Nikolas London, MD
PDS May Reduce Treatment Burden in High-Need Patients
Yasha Modi, MD, discusses phase 4 data on the port delivery system in patients with nAMD who previously required frequent anti-VEGF injections.
By Yasha Modi, MD
Long-Term PDS Data Show Sustained Disease Control
Jeremy Wolfe, MD, MS, discusses long-term vision, fluid control, safety, and refill intervals with the port delivery system for nAMD.
By Diana V. Do, Jeremy Wolfe, MD, MS
An Invitation to Argentina
Retina specialists preview the clinical and surgical program planned for the Argentine Society of Retina and Vitreous (Sociedad Argentina de Retina y Vítreo, or SARyV), November 5-7 in Ushuaia, Argentina.
By Patricio G. Schlottmann, MD, Constanza Rittatore, MD, Aníbal Francone, MD
Ultrawidefield Imaging in Sickle Cell Retinopathy
Adrienne Scott, MD, discusses a prospective case series evaluating ultrawidefield imaging of macular and peripheral pathology in patients with sickle cell disease.
By Adrienne W. Scott, MD
The Regulatory Path Ahead for Axpaxli
Peter Kaiser, MD, explains how the SOL-1 results and discussions with the FDA are shaping Ocular Therapeutix's planned NDA submission.
By Peter K. Kaiser, MD, Diana V. Do
Encelto Shows Outer Retinal Preservation in MacTel
Jay Chhablani, MD, reviews a post hoc analysis showing effects on ellipsoid zone and outer nuclear layer measures, along with a modest reduction in cavitation volume.
By Jay Chhablani, MD
Inside the ARCHER II Trial
Ashkan Abbey, MD, explains how phase 2 findings informed the design and patient population of the phase 3 vonaprument trial in geographic atrophy.
By Ashkan M. Abbey, MD
The Road Ahead for Optogenetics
Allen C. Ho, MD, FACS, discusses the FDA’s acceptance of the BLA for MCO-010 and the potential of optogenetic therapy for severe vision loss in retinitis pigmentosa.
By Allen C. Ho, MD, Diana V. Do
Turning Structural OCT Into Functional Data
Roger Goldberg, MD, MBA, discusses OCT-F, a new AI-enabled method that uses structural OCT to estimate retinal sensitivity in geographic atrophy.
By Roger A. Goldberg, MD, MBA